Health Care [ 12/12 ] | Biotechnology [ 67/73 ]
NASDAQ | Common Stock
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally.
The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs.
In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -0.23 Increased by +89.37% | -0.25 Increased by +9.84% |
| Mar 25, 25 | -1.93 Increased by +6.76% | -0.40 Decreased by -382.50% |
| Nov 7, 24 | -0.98 Decreased by -20.99% | -0.44 Decreased by -122.73% |
| Aug 8, 24 | -0.36 Increased by +66.36% | -0.56 Increased by +35.71% |
| Apr 12, 24 | -2.12 Decreased by -10.70 K% | -1.14 Decreased by -85.96% |
| Dec 31, 23 | -2.07 Decreased by -417.50% | -0.99 Decreased by -109.09% |
| Nov 9, 23 | -0.81 Decreased by -912.50% | -1.01 Increased by +19.80% |
| Aug 10, 23 | -1.07 Decreased by -1.43 K% | -0.87 Decreased by -22.99% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 2.14 M Increased by +1.11 K% | -6.67 M Increased by +26.93% | Decreased by -312.02% Increased by +93.98% |
| Dec 31, 24 | 1.49 M Increased by +373.25% | -33.51 M Decreased by -109.55% | Decreased by -2.26 K% Increased by +55.72% |
| Sep 30, 24 | 115.00 K Decreased by -73.19% | -13.49 M Decreased by -107.94% | Decreased by -11.73 K% Decreased by -675.69% |
| Jun 30, 24 | 104.00 K Decreased by -77.54% | -4.53 M Increased by +45.64% | Decreased by -4.36 K% Decreased by -142.02% |
| Mar 31, 24 | 176.00 K Decreased by -40.74% | -9.13 M Increased by +79.86% | Decreased by -5.19 K% Increased by +66.02% |
| Dec 31, 23 | 314.00 K Increased by +14.60% | -15.99 M Increased by +64.44% | Decreased by -5.09 K% Increased by +68.97% |
| Sep 30, 23 | 429.00 K Increased by +540.30% | -6.49 M Increased by +31.30% | Decreased by -1.51 K% Increased by +89.27% |
| Jun 30, 23 | 463.00 K Increased by +95.36% | -8.33 M Decreased by -3.67% | Decreased by -1.80 K% Increased by +46.93% |